Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

A tool for reliable self-home blood pressure monitoring designed according to the European Society of Hypertension recommendations: The Microlife WatchBP Home monitor

Stergiou, George S.a; Jaenecke, Berndb; Giovas, Periklis P.a; Chang, Arronc; Chung-Yueh, Yenc; Tan, Ty-Minhb

doi: 10.1097/MBP.0b013e32809efa38
Devices and Technology

Background Self-blood pressure monitoring by patients at home (HBPM) is being increasingly used in clinical practice and has been endorsed by hypertension societies as an important adjunct to the conventional office blood pressure measurements. Several problems, however, exist regarding the application of HBPM in practice, such as device inaccuracy, observer bias and misreporting, variable monitoring schedule and variable method for summarizing measurements. The European Society of Hypertension Working Group (ESH-WG) on Blood Pressure Monitoring has published detailed recommendations on how to apply HBPM in clinical practice.

Objective The Microlife WatchBP Home monitor is designed to provide reliable and unbiased self-blood pressure monitoring by patients at home, strictly according to the ESH-WG recommendations.

Design Dual-function automated oscillometric monitor for HBPM in the arm, with memory, PC link capacity and embedded monitoring schedule. The device has a Usual mode for casual HBPM and a Diag (diagnostic) mode for HBPM strictly according to the ESH-WG proposed schedule (duplicate morning and evening measurements for 7 days). Readings are averaged by the device after exclusion of the initial day according to ESH-WG recommendations and can be transferred to PC for storing or printing. A pilot study in hypertensive patients with previous experience in HBPM suggested that the device is user-friendly and well accepted.

Conclusion The Microlife WatchBP Home monitor is a novel device that provides a reliable and unbiased assessment of home blood pressure strictly according to the ESH recommendations.

aHypertension Center, Third University Department of Medicine, Sotiria Hospital, Athens, Greece

bMicrolife AG, Heerbrugg, Switzerland

cMicrolife Corporation, Taipei, R.O.C Taiwan

Correspondence to George S. Stergiou, MD, Hypertension Center, Third University Department of Medicine, Sotiria Hospital, 152 Mesogion Avenue, Athens 11527, Greece

Tel: +30 (210) 776 3117; fax: +30 (210) 771 9981; e-mail:

Received 16 September 2006 Revised 24 October 2006 Accepted 24 October 2006

© 2007 Lippincott Williams & Wilkins, Inc.